Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
115 hedge funds and large institutions have $206M invested in Aratana Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 39 increasing their positions, 28 reducing their positions, and 9 closing their positions.
189% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 9
39% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 28
15% more funds holding
Funds holding: 100 → 115 (+15)
7% more capital invested
Capital invested by funds: $193M → $206M (+$12.9M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.11M |
| 2 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$1.88M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.47M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.43M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
Engaged Capital
Newport Beach,
California
|
-$3.53M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.77M |
| 3 |
GAI
General American Investors
New York
|
-$1.68M |
| 4 |
Goldman Sachs
New York
|
-$1.56M |
| 5 |
Renaissance Technologies
New York
|
-$1.18M |
PETX Hedge Fund Activity: Q4 2018 in Review
115 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q4 2018, worth a combined $206M — up 6.7% from $193M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PETX positions and 9 closed out — a net gain of 17 holders — while 39 added to existing stakes and 28 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.11M. The largest seller was Engaged Capital, cutting an estimated $3.53M.
- 115 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q4 2018, up from 100 in Q3 2018.
- Funds reported $206M of Aratana Therapeutics, Inc. stock for Q4 2018, up 6.7% quarter-over-quarter.
- 26 funds opened new Aratana Therapeutics, Inc. positions in Q4 2018 and 9 closed out, a net change of +17 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q4 2018 was Millennium Management, an estimated $2.11M added.
- The largest Aratana Therapeutics, Inc. seller in Q4 2018 was Engaged Capital, an estimated $3.53M sold.
Based on aggregated 13F filings for Q4 2018.